Sandoz Faces New Competition as Biocon Targets Ozempic and Wegovy Markets
Sandoz Group AG’s stock price has risen due to its focus on generic and biosimilar medicines, but the company faces a challenge from Biocon’s plans to file for regulatory approvals of generic versions of popular diabetes medications.
2 minutes to read